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ABSTRACT
Background. Early recognition of acute kidney injury (AKI) is
important. It frequently develops ﬁrst in the community.
KDIGO-based AKI e-alert criteria may help clinicians recog-
nize AKI in hospitals, but their suitability for application in
the community is unknown.
Methods. In a large renal cohort (n = 50 835) in one UK health
authority, we applied the NHS England AKI ‘e-alert’ criteria to
identify and follow three AKI groups: hospital-acquired AKI
(HA-AKI), community-acquired AKI admitted to hospital within
7 days (CAA-AKI) and community-acquired AKI not admitted
within 7 days (CANA-AKI). We assessed how AKI criteria oper-
ated in each group, based on prior blood tests (number and time
lag). We compared 30-day, 1- and 5-year mortality, 90-day renal
recovery and chronic renal replacement therapy (RRT).
Results. In total, 4550 patients met AKI e-alert criteria, 61.1%
(2779/4550) with HA-AKI, 22.9% (1042/4550) with CAA-AKI
and 16.0% (729/4550) with CANA-AKI. The median number
of days since last blood test differed between groups (1, 52 and
69 days, respectively). Thirty-day mortality was similar for HA-
AKI and CAA-AKI, but signiﬁcantly lower for CANA-AKI
(24.2, 20.2 and 2.6%, respectively). Five-year mortality was
high in all groups, but followed a similar pattern (67.1, 64.7
and 46.2%). Differences in 5-year mortality among those not
admitted could be explained by adjusting for comorbidities
and restricting to 30-day survivors (hazard ratio 0.91, 95% con-
ﬁdence interval 0.80–1.04, versus hospital AKI). Those with
CANA-AKI (versus CAA-AKI) had greater non-recovery at
90 days (11.8 versus 3.5%, P < 0.001) and chronic RRT at 5
years (3.7 versus 1.2%, P < 0.001).
Conclusions. KDIGO-based AKI criteria operate differently in
hospitals and in the community. Some patients may not require
immediate admission but are at substantial risk of a poor long-
term outcome.
Keywords: acute kidney injury, delivery of health care,
epidemiology, primary health care, survival analysis
INTRODUCTION
Acute kidney injury (AKI) is common, serious and under-
recognized [1, 2]. The Kidney Disease: Improving Global Out-
comes (KDIGO) creatinine change criteria are typically used
for diagnosis [3]. There is a need to recognize AKI early to min-
imize preventable harm [4]. This has led to growing international
interest in AKI ‘e-alerts’, based on KDIGO criteria, to warn
clinicians when serum creatinine is rising abruptly in hospital
patients [5–8]. However, an AKI episode is often already estab-
lished before a patient reaches hospital [6, 9, 10]. AKI e-alerts
are therefore also being considered for the community [5].
The KDIGO criteria deﬁne AKI based on changes in creatin-
ine that are ‘presumed to have occurred within the prior 7 days’
[3]. Not all patients have had tests within a week, and this has led
to pragmatic adaptations when operationalizing the KDIGO cri-
teria in clinical practice (e-alerts) and in clinical research [11].
For example, AKI e-alerts developed by NHS England use
three different look-back periods to accommodate this difﬁculty© The Author 2016. Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of theCreativeCommonsAttribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
in any medium, provided the original work is properly cited.
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[5]. We have previously shown that these adaptations involve a
‘trade-off’ between identifying all clinically relevant AKI patients
and misclassifying patients who do not have AKI [11, 12]. Im-
portantly, this trade-off may not be the same for patients in the
community who do not receive blood tests with the same regu-
larity. This has consequences for whether the same criteria can be
used to detect relevant AKI patients both in and out of hospital.
While it is acknowledged that AKI frequently emerges ﬁrst in
the community, this is based onhospital-only studies that identiﬁed
patientswho alreadyhad an elevated serumcreatinine at the timeof
hospital admission [6, 9, 10]. These studies do not describe AKI oc-
curring in the community that has not led to hospital admission.
Hospital-only studies also cannot conﬁrm whether the same cri-
teria perform consistently in all clinical settings or remain clinically
relevant without the context of a hospital admission. While one
previous study has focussed on AKI in the community without
hospital admission, it did not use a conventional application of
theKDIGOcriteria and did not provide acomparisonwith patients
who were subsequently admitted or already in hospital [13].
Grampian Laboratory Outcomes Morbidity and Mortality
Study-II (GLOMMS-II) is a population cohort linking national
and regional data sources in a single UK health authority (adult
population 438 332 [14]). It has been extensively used in renal re-
search, including in the study of AKI deﬁnitions, and has been de-
scribed in detail previously [11, 15–17]. Uniquely, all biochemistry
is provided by a single biochemistry service, regardless of clinical
location (inpatient, outpatient, community), ensuring that AKI in
both primary and secondary care has been appropriately repre-
sented. Data linkage enables follow-up without formal patient re-
cruitment, which minimizes any selection biases.
The aim of this study was to understand whether AKI e-alert
criteria used in hospitals have similar implications when
applied in the community, including those later admitted
and not admitted. We used GLOMMS-II to describe three
AKI groups: hospital-acquired AKI (HA-AKI), community-
acquired AKI patients who were admitted to hospital within
7 days (CAA-AKI) and community-acquired AKI not admitted
within 7 days (CANA-AKI).We described the characteristics of
patients in each group, explored how the AKI e-alert criteria
performed and compared their short- and long-term outcomes.
MATERIALS AND METHODS
Population
GLOMMS-II is a population cohort developed through
novel data linkage of regional biochemistry to hospital episode
data and the Scottish Renal Registry (SRR) for chronic renal re-
placement therapy (RRT), morbidity and outcomes [11, 16].
Information Services Division (ISD) Scotland refreshed these
linkages using the community health index (CHI), a unique
identiﬁer for all residents in Scotland, to connect the timing
of each AKI episode to individual hospital admissions. There
were no patients without a CHI indexed in the ISD population
‘spine’, meaning that all records were linkable. ISD reports a
precision of 99.9% for record linkages [18]. Use of GLOMMS-II
was approved by regional research ethics and privacy advisory
committees, and managed in Grampian Data Safe Haven [19].
GLOMMS-II includes 50 835 patients, 29 729 with at least
one abnormal (estimated glomerular ﬁltration rate, eGFR
<60 mL/min/1.73 m2) result in 2003, and a ∼20% sample
(21 106) of all those with normal results in 2003, with biochem-
istry from 1999 to 2009 for baseline and follow-up (Figure 1). A
single biochemistry service processed all blood samples. All
serum creatinines were isotope dilution mass spectrometry
(IDMS) aligned. Patients with prior chronic RRTwere excluded
from this analysis.
Exposure—hospital-acquired and community-acquiredAKI
We applied the NHS England AKI e-alert Criteria 1–3
(Table 1) to identify AKI in 2003. We deﬁned the ﬁrst blood re-
sult meeting AKI criteria as the start of an ‘AKI episode’, and
the corresponding value of the prior ‘look-back’ test was used
as the ‘baseline’. From this baseline, we assigned AKI severity
Stages 1–3 at initial diagnosis, and at peak severity using the
highest creatinine within 90 days of AKI onset (Table 1). We
have previously reported the application and good diagnostic
performance of this algorithm elsewhere [11, 12].
F IGURE 1 : Flowchart of GLOMMS II cohort including AKI sub-
groups. AKI, acute kidney injury; HA-AKI, hospital AKI; CAA-AKI,
community AKI admitted within 7 days; CANA-AKI, community
AKI not admitted within 7 days. In sensitivity analysis, the proportions
after multiplying out the sampled fraction were 61.0% HA-AKI, 22.1%
CAA-AKI and 16.8% CANA-AKI.
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We compared three AKI groups (Table 1): HA-AKI, CAA-
AKI and CANA-AKI. We categorized AKI groups by linking
the ﬁrst AKI episode in 2003 to the closest hospital admission.
AKI was ‘hospital-acquired’ if it developed in patients already
in hospital (≥1 day) (HA-AKI). AKI was ‘community-
acquired’ if it ﬁrst developed in the community or on the
ﬁrst day of hospital admission ([6, 20]). We subcategorized
community-acquired AKI into those subsequently admitted
to hospital within 7 days (CAA-AKI) and those not admitted
within 7 days (CANA-AKI).
Based on previous work, we recognized that some patients
with smaller creatinine rises might have misclassiﬁed chronic
kidney disease (CKD) [12], and that this might vary between
AKI groups. Therefore, we also provided an alternative deﬁn-
ition for AKI by restricting the AKI criteria to those who also
had a doubling of serum creatinine during the AKI episode.
By excluding patients with mild creatinine rises, this alternative
deﬁnition misclassiﬁes fewer patients with CKD [12].
Outcomes
AKI patients were followed for up to 5 years from the date of
ﬁrst AKI. We described the operational performance of AKI
criteria by reporting which AKI criteria were met on initial
diagnosis, the number of days since last prior blood test and
the number of blood tests in the prior year. We also reported
initial and peak AKI severity stage for each AKI group and
the number of patients meeting AKI criteria who also had a
doubling of serum creatinine. We recorded mortality (from
the national death registry) at 30 days, and 1 and 5 years after
AKI onset.We determined renal recovery at 90 days, comparing
the last creatinine within 90 days of AKI with the baseline cre-
atinine (Table 1). We assessed whether patients had any repeat
tests within 7 and 90 days of AKI onset. Finally, we recorded
chronic RRT at 1 and 5 years. We deﬁned chronic RRT using
UK renal registry and SRR criteria [21].
Covariates of interest
We reported age, sex, level of deprivation (most deprived
quintile of the Scottish Index of Multiple Deprivation, SIMD)
and rural location (settlement of <3000 people) [22]. We iden-
tiﬁed patients in nursing homes or residential care at the time of
AKI, the annual quarter in which AKI occurred, and, if admit-
ted, the specialty involved during admission with the following
priority where more than one was involved: critical care, surgi-
cal, care of the elderly, medical and ‘other’ ward (e.g. obstetrics,
psychiatry). We collected all comorbidity events in the previous
5 years using International Classiﬁcation of Diseases (ICD-10)
codes for Charlson comorbidities (see Table 2 for list) as previous-
ly described and validated [23, 24]. The four-variable Modiﬁca-
tion of Diet in Renal Disease (MDRD) eGFR is currently
reported in the health region, andwe used this to describe baseline
renal function in four eGFR groups: normal ≥60, mild 45–59,
moderate 30–44 and severe impairment <30 mL/min/1.73 m2.
Analysis
We described patient characteristics and the AKI e-alert cri-
teria performance in each of the three AKI groups. Previous
studies have separated hospital and community AKI based on
different time cut-offs for AKI presentation (e.g. AKI on the day
of admission only or AKI up to 48 h after hospital admission)
[6, 9]. Therefore, we also reported the number of patients newly
meeting AKI criteria on each admission day and their corre-
sponding 30-day mortality. In addition, as our cohort included
a 20% sample of patients with normal results, we checked in a
sensitivity analysis that the proportions in each AKI group were
similar after multiplying out the sampled fraction.
We compared 30-day, and 1- and 5-year mortality between
AKI groups and plotted Kaplan–Meier survival curves ﬁrst un-
adjusted, then limited to 30-day survivors, and then limited to
30-day survivors and adjusted for age, sex, baseline eGFR and
all Charlson comorbidities (listed in Table 2). We used Cox
Table 1. Description of AKI criteria, AKI group allocation and 90-day recovery status
Deﬁnition Description
AKI criteria (1 of 3 required)
Criterion 1 Serum creatinine ≥1.5 times higher than the median of all creatinine values 8–365 days ago
Criterion 2 Serum creatinine ≥1.5 times higher than the lowest creatinine within 7 days
Criterion 3 Serum creatinine >26 µmol/L higher than the lowest creatinine within 48 h
AKI severity stage
Stage 1 Rise in creatinine of >26 µmol/L or index/baseline ≥1.5 and <2
Stage 2 Index/baseline ≥2 and <3
Stage 3 Index/baseline ≥3; or ≥1.5 and index creatinine >354 µmol/L (or 3 times the upper reference interval if age <18 years)
AKI group
HA-AKI Patient in hospital for >1 day when AKI developed
CAA-AKI AKI presenting in the community and admitted within 7 days or presenting on the ﬁrst day of hospital admission
CANA-AKI AKI presenting in the community. Patient not subsequently admitted within 7 days
90-day recovery status
Complete recovery Latest creatinine within 90 days of AKI <1.2 times higher than the baseline creatinine
Partial recovery Latest creatinine within 90 days of AKI <1.5 and ≥1.2 times higher than the baseline creatinine
Non-recovery Lowest creatinine within 90 days of AKI ≥1.5 times higher than the baseline creatinine
‘Untested’ No repeat blood tests taken within 90 days of AKI diagnosis
AKI, acute kidney injury; HA-AKI, hospital AKI; CAA-AKI, community AKI admitted within 7 days; CANA-AKI, community AKI not admitted within 7 days.
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proportional hazards regression to determine the unadjusted
and adjusted risk of death for community-acquired AKI admit-
ted and not admitted relative to hospital-acquired AKI both in
the short term (30 days) and in the long term (subsequent 5
years in 30-day survivors). We checked the proportional ha-
zards assumption using log–log survival plots. Continuous
variables (age, baseline eGFR) were tested with linear, quadratic
terms and in categories to determine whether the linear term
was adequate. As a sensitivity analysis to provide additional
context for AKI outcomes, we also reported 5-year mortality
for all people admitted to hospital in 2003, with and without
renal impairment at hospital admission (eGFR < or ≥60 mL/
min/1.73 m2), who did not experience AKI in 2003.
Between AKI groups, we compared recovery status at
90 days, the number of patients who received repeat blood
tests within 7 and 90 days and the number of patients receiving
chronic RRT at 1 and 5 years. Analysis was performed using
Stata/SE 13.0 (StataCorp).
RESULTS
Cohort characteristics
Of 50 835 patients, 4550 (9.0%) had AKI (Figure 1). The
majority (61.1%) were HA-AKI, but a substantial proportion
occurred in the community (22.9% CAA-AKI and 16.0%
CANA-AKI). Those with HA-AKI were older, received more
critical care and had more comorbidities (Table 2).
Performance of AKI criteria
We compared each AKI group to determine whether differ-
ences in the testing pattern between community and hospitalized
patients impacted on how the AKI criteria operated (Table 3).
Compared with CAA-AKI and CANA-AKI, those with
HA-AKI had more prior tests (median number 7 versus 4 and
5, respectively) and more recent tests (median days between
AKI and last test 1 versus 52 and 69). Accordingly, therewas sub-
stantial difference in how the AKI criteria operated. Those with
Table 2. Cohort characteristics by AKI group
HA-AKI CAA-AKI CANA-AKI
n 2779 1042 729
Median age in years (IQR) 77 (68–84) 73 (61–82) 72 (60–79)
Age ≥70 years 1994 (71.8)a 606 (58.2) 408 (56.0)
Female 1455 (52.4) 542 (52.0) 465 (63.8)
Baseline eGFR group (mL/min/1.73 m2)
≥60 1649 (59.3) 681 (65.4) 451 (61.9)
45–59 527 (19.0) 196 (18.8) 129 (17.7)
30–44 391 (14.1) 117 (11.2) 104 (14.3)
0–29 212 (7.6) 48 (4.6) 45 (6.2)
Year quarter
January–March 807 (29.0) 321 (30.8) 215 (29.5)
April–June 686 (24.7) 259 (24.9) 173 (23.7)
July–September 608 (21.9) 222 (21.3) 182 (25.0)
October–December 678 (24.4) 240 (23.0) 159 (21.8)
Specialty (if admitted)
Medicine 879 (31.6) 499 (47.9)
Elderly care 425 (15.3) 160 (15.4)
Surgical 466 (16.8) 194 (18.6)
Critical care 787 (28.3) 148 (14.2)
Other 222 (8.0) 41 (3.9)
Patient location
Residential care 119 (4.3) 92 (8.8) 22 (3.0)
Deprived area (SIMD) 255 (9.2) 99 (9.5) 48 (6.6)
Rural location 752 (27.1) 252 (24.2) 223 (30.6)
Charlson comorbidities from admissions in previous 5 yearsb
Myocardial infarction 578 (20.8) 77 (7.4) 62 (8.5)
Cardiac failure 601 (21.6) 109 (10.5) 107 (14.7)
Peripheral vascular disease 326 (11.7) 81 (7.8) 37 (5.1)
Cerebrovascular disease 444 (16.0) 81 (7.8) 42 (5.8)
Dementia 186 (6.7) 44 (4.2) 16 (2.2)
Chronic pulmonary disease 445 (16.0) 140 (13.4) 52 (7.1)
Rheumatic 134 (4.8) 37 (3.6) 39 (5.3)
Peptic ulcer 153 (5.5) 47 (4.5) 27 (3.7)
Liver disease—mild 95 (3.4) 27 (2.6) 20 (2.7)
Liver disease—severe 50 (1.8) 11 (1.1) 11 (1.5)
Diabetes—uncomplicated 432 (15.5) 156 (15.0) 90 (12.3)
Diabetes—complicated 80 (2.9) 33 (3.2) 9 (1.2)
Hemiplegia 63 (2.3) 13 (1.2) 6 (0.8)
Malignancy 549 (19.8) 214 (20.5) 95 (13.0)
Metastatic malignancy 177 (6.4) 77 (7.4) 23 (3.2)
Any vascular diseasec 1542 (55.5) 370 (35.5) 228 (31.3)
0 diseases 573 (20.6) 398 (38.2) 371 (50.9)
1 disease 894 (32.2) 324 (31.1) 174 (23.9)
2 diseases 751 (27.0) 191 (18.3) 118 (16.2)
3 or more diseases 561 (20.2) 129 (12.4) 66 (9.0)
AKI, acute kidney injury; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile
range; HA-AKI, hospital AKI; CAA-AKI, community AKI admitted within 7 days;
CANA-AKI, community AKI not admitted within 7 days; SIMD, Scottish Index of
Multiple Deprivation.
aPercentage of group unless otherwise speciﬁed.
bHuman immunodeﬁciency virus data suppressed to avoid identiﬁcation.
cVascular disease includes peripheral vascular disease, diabetes, cerebrovascular disease,
myocardial infarction and cardiac failure.
Table 3. Performance of AKI criteria by AKI group
HA-AKI CAA-AKI CANA-AKI
n (%)a n (%)a n (%)a
n 2779 1042 729
AKI criteria met at ﬁrst presentation
Criterion 1 (8–365 days) 1209 (43.5)a 968 (92.9) 685 (94.0)
Criterion 2 (7 days) 1246 (44.8) 111 (10.7) 47 (6.4)
Criterion 3 (48 h) 1624 (58.4) 50 (4.8) 31 (4.3)
Criterion 1 met only 606 (21.8) 901 (86.5) 661 (90.7)
Median number of tests in
previous year (IQR)
7 (3–13) 4 (2–11) 5 (2–11)
Median days since last
prior test (IQR)
1 (1–3) 52 (14–140) 69 (22–168)
Initial AKI stage at ﬁrst detection
1 2337 (84.1) 688 (66.0) 624 (85.6)
2 316 (11.4) 211 (20.2) 76 (10.4)
3 126 (4.5) 143 (13.7) 29 (4.0)
Peak AKI stage over 90 days
1 1868 (67.2) 554 (53.2) 564 (77.4)
2 574 (20.7) 272 (26.1) 97 (13.3)
3 337 (12.1) 216 (20.7) 68 (9.3)
Doubling of creatinine 900 (32.4) 480 (46.1) 155 (21.3)
AKI, acute kidney injury; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile
range; HA-AKI, hospital AKI; CAA-AKI, community AKI admitted within 7 days;
CANA-AKI, community AKI not admitted within 7 days.
aPercentages reported for each group unless otherwise speciﬁed.
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HA-AKImore frequentlymet AKI Criteria 2 and 3 (change from
prior 7 days), whereas those with CAA-AKI and CANA-AKI
more frequently met AKI Criterion 1 (change from prior
8–365 days). Those with CAA-AKI also experienced the greatest
creatinine rises (based on AKI stage and doubling of creatinine).
Day of AKI detection
As previous studies separated hospital and community AKI
at different time points, we assessed whether this would impact
on the proportion of AKI attributed to the community and the
subsequent mortality (Figure 2). A total of 38.9% of all AKI
events presented in the community or on the day of admission.
Alternative deﬁnitions would have led to a larger proportion
with community AKI (10.2 and 9.3% developed AKI on admis-
sion days 2 and 3, respectively).
Outcomes—mortality
Thirty-day mortality was similar for HA-AKI and CAA-AKI,
but lower for CANA-AKI (respectively, 24.2, 20.2 and 2.6%)
(Table 4). At 5 years, mortality was substantial in all groups
but still lower for CANA-AKI (67.1, 64.7 and 46.2%). However,
as shown in the Figure 3 survival curves, the mortality difference
(Figure 3A) was attenuated by excluding patients who died with-
in 30 days (Figure 3B) and adjusting for age and comorbidities
(Figure 3C). To provide a context, we also determined 5-year
mortality for those admitted to hospital who did not have AKI.
Five-year mortality was 41.3% in those with baseline renal
impairment (n = 6486) and 20.7% in those with normal baseline
function (n = 7584).
In multivariate analysis (reference group HA-AKI),
30-day mortality was similar for CAA-AKI versus HA-AKI
(adjusted hazard ratio, HR 1.06, 95% conﬁdence interval,
F IGURE 2 : Number of patients with newly detected acute kidney injury (AKI) each day of admission and subsequent 30-day mortality (%).
*Number of days in brackets represents as a denominator the median of number of days exposed in the group during that admission period. Error
bars represent 95% conﬁdence intervals (CI).
Table 4. Outcomes in hospital and community AKI
HA-AKI CAA-AKI CANA-AKI
n (%) n (%) P-value* n (%) P-value*
n 2779 1042 729
30-day mortality 673 (24.2) 211 (20.2) 0.010 19 (2.6) <0.001
1-year mortality 1192 (42.9) 441 (42.3) 0.751 124 (17.0) <0.001
5-year mortality 1864 (67.1) 674 (64.7) 0.163 337 (46.2) <0.001
1-year chronic RRT 27 (1.0) 5 (0.5) 0.137 20 (2.7) <0.001
5-year chronic RRT 44 (1.6) 12 (1.2) 0.323 27 (3.7) <0.001
Median days to chronic RRT among those who received chronic RRT (IQR) 204 (77–468) 490 (49–845) 0.346 192 (59–482) 0.943
Recovery status at 90 days
Dead 883 (31.8) 318 (30.5) 46 (6.3)
Chronic RRT 13 (0.5) 2 (0.2) 9 (1.2)
Untested 203 (7.3) 102 (9.8) 209 (28.7)
No recovery 94 (3.4) 36 (3.5) 86 (11.8)
Partial recovery 316 (11.4) 71 (6.8) 128 (17.6)
Full recovery 1270 (45.7) 513 (49.2) <0.001 251 (34.4) <0.001
Repeat testing (among those alive and without RRT)
No repeat tests at 7 days 444 (18.6) 187 (20.4) 0.251 593 (81.7) <0.001
No repeat tests at 90 days 203 (10.8) 102 (14.1) 0.017 209 (31.0) <0.001
AKI, acute kidney injury; RRT, renal replacement therapy; IQR, interquartile range; HA-AKI, hospital AKI; CAA-AKI, community AKI admitted within 7 days; CANA-AKI, community
AKI not admitted within 7 days.
*P-values versus HA-AKI, χ2 test for comparing proportions, Wilcoxon rank-sum for non-parametric comparison.
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CI 0.89–1.25), but lower in CANA-AKI (HR 0.13, 95% CI
0.07–0.18) (Table 5). Among those still alive at 30 days, ad-
justed 5-year mortality in CANA-AKI was not signiﬁcantly
lower versus HA-AKI (HR 0.91, 95% CI 0.80–1.04). These re-
sults were similar when the analysis was restricted to only
those with a doubling of serum creatinine. In summary, mor-
tality was similar for HA-AKI and CAA-AKI. For CANA-
AKI, while short-term mortality was low, the long-term
mortality was substantial and not statistically signiﬁcantly
different after adjustment.
Outcomes—recovery, repeat tests and chronic RRT
As reported in Table 4, non-recovery at 90 days was most
common in CANA-AKI. CANA-AKI patients also frequently
had no repeat test within 7 days (81.3%) and 90 days (31.0%)
of AKI onset. At 5 years, a higher percentage of CANA-AKI pa-
tients had initiated chronic RRT than HA-AKI or CAA-AKI
(3.7 versus 1.6 and 1.2%, respectively). In further analysis of
those who initiated RRT, the median number of days since
last test prior to the AKI episode was not prolonged in any
group (33 versus 1 and 14 days, respectively), suggesting that
misclassiﬁcation of slow CKD progression would not account
for the increased RRT in CANA-AKI, although rapid progres-
sion could still be an explanation.
DISCUSSION
Despite AKI frequently initiating in the community, and des-
pite the need for early recognition of AKI, this is the ﬁrst
large population-based study to explore the implications of ap-
plying the same systematic AKI criteria to patients both admit-
ted and not admitted within 7 days. Using NHS England AKI
‘e-alert’ criteria, we report that a substantial proportion of AKI
originates in the community, but that AKI criteria operate dif-
ferently in the community due to less frequent testing. Never-
theless, in those admitted, HA-AKI and CAA-AKI had similar
outcomes despite differing antecedent circumstances and base-
line characteristics. Notably, 16% of all AKI was not associated
with admission within 7 days (CANA-AKI). In this group, the
short-term mortality was low, but long-term mortality was
substantial.
The high rate of chronic RRT (1 in 30) and lack of repeat
testing in CANA-AKI was unexpected. One explanation
could be misclassiﬁcation of rapidly progressing CKD patients
when the AKI criteria are applied outside the hospital setting.
The low 30-day mortality might also suggest a less ‘acute’ insult
in CANA-AKI. However, the creatinine changes were recent
even among those not admitted (median 33 days) and this sug-
gests rapid deterioration. Thus, even if AKI criteria misclassify
F IGURE 3 : Kaplan–Meier survival in patients with HA-AKI, CAA-AKI and CANA-AKI (A) unadjusted; (B) limited to 30-day survivors; (C)
adjusted (for age, baseline eGFR and all Charlson comorbidities as in Table 5) and limited to 30-day survivors. CAA-AKI, community AKI
admitted within 7 days; CANA-AKI, community AKI not admitted within 7 days; HA-AKI, hospital acquired AKI. Note that survival curves in
(B) and (C) start to fall from 0 years + 30 days. Mortality for CANA-AKI was signiﬁcantly reduced in (B) but not in (C), as reported in Table 5.
Table 5. Thirty-day mortality and 5-year mortality (in 30-day survivors) by AKI group
HR (95% CI) for short-term mortality (within 30 days) HR (95% CI) for long-term mortality (in 30-day survivors)
Unadjusted Age–sex adjusted Comorbidity
adjusteda
Unadjusted Age–sex adjusted Comorbidity
adjusteda
HA-AKI 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.0 (ref) 1.00 (ref)
CAA-AKI 0.86 (0.73–1.01) 0.95 (0.81–1.12) 1.06 (0.89–1.25) 1.00 (0.90–1.11) 1.16 (1.04–1.29) 1.21 (1.09–1.35)
CANA-AKI 0.10 (0.06–0.16) 0.11 (0.07–0.18) 0.13 (0.08–0.22) 0.68 (0.60–0.77) 0.83 (0.74–0.94) 0.91 (0.80–1.04)
HA-AKI and doubling of creatinineb 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
CAA-AKI and doubling of creatinineb 0.73 (0.59–0.90) 0.78 (0.63–0.96) 0.93 (0.74–1.16) 0.99 (0.84–1.18) 1.08 (0.90–1.28) 1.15 (0.96–1.38)
CANA-AKI and doubling of creatinineb 0.16 (0.09–0.31) 0.19 (0.10–0.35) 0.20 (0.11–0.38) 0.76 (0.59–0.98) 0.94 (0.72–1.21) 1.03 (0.78–1.35)
AKI, acute kidney injury; HR, hazard ratio; CI, conﬁdence interval; HA-AKI, hospital AKI; CAA-AKI, community AKI admitted within 7 days; CANA-AKI, community AKI not admitted
within 7 days.
aAdjustment includes age, sex, baseline eGFR, history of myocardial infarction, cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease,
rheumatic disease, mild chronic liver disease, severe chronic liver disease, diabetes mellitus with complications, diabetes mellitus without complications, hemiplegia, malignancy, metastatic
malignancy and human immunodeﬁciency virus.
bDoubling of serum creatinine during AKI episode used as an alternative deﬁnition of AKI excluding those with mild creatinine rises.
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some ‘CKD’ patients in the community, they do still identify a
group of patients with signiﬁcant recent kidney function change,
and the lack of repeat testing in this group is therefore still a
concern.
This analysis is consistent with previous studies. We conﬁrm
that a high proportion of AKI in hospital ﬁrst originates in the
community. While two previous studies reported an even high-
er proportion [6, 9], this can be explained by the inclusion of
patients developing AKI up to 48 h after admission in one
study (many of which we classiﬁed as HA-AKI) [9], and the
assumption of normal baseline renal function if baseline was
missing in the other study [6], which could lead to some
CKD patients admitted from the community being misclassi-
ﬁed as AKI [25]. Our analysis adds greater detail by revealing
that AKI criteria perform differently in patients who develop
AKI in the community, and that hospital-based studies over-
look a sizable group of patients whomeet the same AKI criteria,
but are not admitted within 7 days. Our short-term mortality
ﬁndings among HA-AKI (24.2%) and CAA-AKI (20.2%)
were also similar to previous reports (28.9 and 20.6%, respect-
ively) [6]. Our analysis goes further by reporting a lower short-
term mortality among those not admitted (2.6%), and a high
incidence of poor long-term outcomes in all groups irrespective
of clinical setting.
This analysis has several strengths: its large size, the use of an
unselected population and the availability of all blood tests in a
single integrated biochemistry service, minimizing the loss of
important baseline data. The use of the widely adopted NHS
‘e-alert’ criteria also makes the ﬁndings relevant for practising
clinicians.
A relative limitation is our dependence on blood results
alone, when the diagnosis of AKI is clinical [3]. We did not in-
clude clinical veriﬁcation, or measures of urine output in our
criteria for AKI or proteinuria for baseline CKD. Without clin-
ical veriﬁcation, patients with baseline CKD can be misclassi-
ﬁed due to either repeat sampling variability or infrequent
testing [12, 26]. We identiﬁed clear differences in how the
same criteria functioned when applied in different clinical
contexts, and indeed, this is one of themain ﬁndings of our ana-
lysis. Nevertheless, regardless of the antecedent circumstances,
we have shown that pragmatic application of KDIGO-based
AKI criteria in the community still identiﬁes clinically relevant
patients and in sensitivity analysis we showed that our mortality
ﬁndings were similar when those with milder creatinine rises
(less than double) were excluded. Another limitation is the
study year (2003). While this enabled a study of long-term
outcomes, recent UK initiatives to raise the awareness of AKI
may lead to improvements in monitoring, and the impact of
these initiatives should be explored in the future [27]. Also,
we described only isolated AKI episodes. Future work should
describe the scale and impact of recurrent AKI events on out-
comes in community patients, preferably with a non-AKI com-
munity comparator group. Future work should also explore
whether there are differences in prescribing patterns (e.g. stop-
ping and restarting drugs) in response to AKI in each of these
clinical settings.
Our analysis contains two key messages for clinicians. First,
many patients ﬁrst met AKI criteria while still in the
community, which suggests that strategies to improve AKI rec-
ognition should involve the community. We recognize that re-
sponding to community blood tests is challenging as many
results return outside of working hours and AKI can occur un-
expectedly. The sizable short-termmortality difference between
community AKI patients who were and were not admitted
within 7 days demonstrates the importance of good clinical
judgement (rather than a reliance on blood tests) to prioritize
acutely ill patients and avoid unnecessary hospital admissions
[28]. Second, regardless of how they operated, AKI criteria
identiﬁed relevant patients in all settings. AKI criteria may op-
erate differently in the community, but these patients still merit
proactive reassessment to conﬁrm or understand why creatin-
ine changes have occurred and manage future risks to avoid re-
currence and long-term complications.
Overall, the pragmatic application of the KDIGOAKI criteria
in the form of e-alerts results in different performance in differ-
ent clinical settings, but they still identify patients at risk of poor
outcomes. Thosewho are not admittedmay have low short-term
mortality, but non-recovery, chronic RRTand long-termmortal-
ity are nevertheless high. Thus, patients meeting AKI criteria in
the communitymay not always require hospital admission, but a
careful review of the clinical circumstances, preventable risk
factors and follow-up is still warranted.
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